ELI-002 2P for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Apr 2021: Trial registered, NCT04853017
  2. 4 Oct 2021: Trial started, NCT04853017

The trials

NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

State
Completed
Phase
Phase 1
People
25 taking part
Started
4 Oct 2021
Primary completion
26 Jan 2023
Arms
ELI-002 2P Cohort 1, ELI-002 2P Cohort 2, ELI-002 2P Cohort 3, ELI-002 2P Cohort 4, ELI-002 2P Cohort 5
Results
Posted on the registry
  1. 21 Apr 2021: Trial registered
  2. 4 Oct 2021: Trial started
  3. 24 Sep 2024: Trial completed
  4. 17 Jan 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.